




MENU

 **RSS** ([http://portal.anvisa.gov.br/noticias/-/asset\\_publisher/FXrpx9qY7FbU/rss?p\\_p\\_cacheability=cacheLevelFull](http://portal.anvisa.gov.br/noticias/-/asset_publisher/FXrpx9qY7FbU/rss?p_p_cacheability=cacheLevelFull))

 Print

## ACCESS TO MEDICINES

# Approved new drug for rare disease

Vyndaqel® is indicated for the treatment of transthyretin amyloidosis, a rare disease that affects adult patients with symptomatic polyneuropathy

**By: Ascom / Anvisa**

**Published: 07/11/2016 16:34**

**Last Modified: 11/07/2016 16:38**

Compartilhar < 25

Tweetar

 Compartilhar 0

ANVISA approved the registration of new drug Vyndaqel® ( *TAFAMIDIS meglumine* ), which is indicated for the treatment of amyloidosis associated with transthyretin, a rare disease that affects adult patients with symptomatic polyneuropathy, in early or intermediate stage to delay peripheral neurologic impairment.

Amyloidosis is a rare, severely debilitating and potentially fatal disease induced by the accumulation of insoluble fibrillar protein (amyloid) within the tissue in amounts sufficient to impair normal function.

The new drug Vyndaqel® ( *meglumine TAFAMIDIS* ) will be manufactured by the American company Catalent Pharma Solutions, LLC, and the owner of the drug registration in Brazil is the company Pfizer Ltda.

new drug ([http://portal.anvisa.gov.br/noticias?p\\_p\\_id=101\\_INSTANCE\\_FXrpx9qY7FbU&p\\_p\\_lifecycle=0&p\\_p\\_state=normal&p\\_p\\_mode=view&p\\_p\\_col\\_id=column-2&p\\_p\\_col\\_count=1&p\\_r\\_p\\_564233524\\_tag=medicamento+novo](http://portal.anvisa.gov.br/noticias?p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=medicamento+novo)) treatment of rare disease  
([http://portal.anvisa.gov.br/noticias?p\\_p\\_id=101\\_INSTANCE\\_FXrpx9qY7FbU&p\\_p\\_lifecycle=0&p\\_p\\_state=normal&p\\_p\\_mode=view&p\\_p\\_col\\_id=column-2&p\\_p\\_col\\_count=1&p\\_r\\_p\\_564233524\\_tag=tratamento+de+doen%C3%A7a+rara](http://portal.anvisa.gov.br/noticias?p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=tratamento+de+doen%C3%A7a+rara))

Back to the top!

 (<http://www.youtube.com/user/anvisao>)

 ([https://twitter.com/anvisa\\_oficial](https://twitter.com/anvisa_oficial))



